Cooper Pharma Limited is a part of the Cooper Pharma Group which was founded in 1959 by a renowned and visionary pharmacist Dr. Bhargava in Delhi. As a leading pharmaceutical manufacturing company in India, Cooper has gradually but vastly spread the reach. It is selling branded generics and ethical segments across 25 states of India. The company has achieved hallmark of quality and efficacy for its 450 distributors and 8,000 retailers. Being one of the topmost drug manufacturers in India, it began exports in the year 1991 with an extensive range of specialized products that were categorized across segments and dosage forms. Eventually, within a couple of years, exports rose and soon accounted for 60% of the total turnover of the organization.
It was in late 2005 that the status of methasterone, in addition to that of four other designer steroids, as an AAS was brought to public awareness by an article published in the Washington Post .  Don Catlin of the UCLA Olympic Laboratory, who conducted the studies, noted methasterone’s similarity to drostanolone. A warning by the FDA was issued soon after to the general public as well as to the distributor, Designer Supplements LLC, for the marketing of this compound.  Methasterone was subsequently added to the World Anti-Doping Agency (WADA) list of prohibited substances in sport.  Despite all of this, methasterone has resurfaced within the supplement industry on several occasions since its banning by WADA. 
After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .